CClinicalTrials.gg
CompletedNCT03558906Updated Jun 15, 2018

TNF-α/HIF-1α/VEGF Pathway in Periodontal Diseases

An observational study in Periodontal Diseases, sponsored by Aydin Adnan Menderes University. Completed. Open to participants aged 27 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-06-15.

Sponsored by Aydin Adnan Menderes University · Observational

Study type
Observational
Model
Case-control
Time perspective
Cross-sectional
Enrollment
87
Ages
27 Years to 45 Years
Sex
All
01

Study summary

This study aimed to investigate gingival crevicular fluid (GCF) and salivary hypoxia inducible factor-1 alpha (HIF-1α), vascular endothelial growth factor (VEGF) and tumor necrosis factor-alpha (TNF-α) levels in different periodontal diseases. A total of 87 individuals, 20 patients with generalized aggressive periodontitis, 20 with chronic periodontitis, 26 with gingivitis and 21 periodontally healthy individuals were included. Whole-mouth and site-specific clinical periodontal parameters including probing depth, clinical attachment level, bleeding on probing, gingival index and plaque index were recorded. GCF and salivary HIF-1α, VEGF and TNF-α levels were measured by enzyme-linked immunosorbent assay. Statistical analysis was performed by using non-parametric tests.

Read the detailed description

Study Population and Clinical Examination

Eighty-seven participants were recruited for the study. Exclusion criteria were as follows: 1) systemic diseases that could affect the periodontium; 2) smoking; 3) current pregnancy or lactation; 4) nonsurgical/surgical periodontal treatment received for the past year; and 5) use of anti-inflammatory and antibiotic drugs within the past 6 months.

The full-mouth clinical periodontal examination included measurement of probing depth (PD), clinical attachment level (CAL), presence of bleeding on probing (BOP), gingival index (GI) and plaque index (PI) at 6 sites per tooth. Presence and extent of alveolar bone loss were assessed radiographically. Based on clinical and radiographic diagnostic criteria proposed by 1999 International Workshop for a Classification of Periodontal Diseases and Conditions, the participants were categorized into four groups.

I. Generalized aggressive periodontitis (GAgP) group (n=20). These individuals had minimum PD ≥6 mm and CAL ≥5 mm on eight or more teeth; at least three of these were other than central incisors or first molars. Radiographic alveolar bone loss was ≥30% of root length affecting at least three permanent teeth other than first molars and incisors. The severe destruction pattern was not commensurate with amount of plaque accumulation or other local risk factors for a given age.

II. Chronic periodontitis (CP) group (n=20). These individuals had at least four non-adjacent teeth with sites with PD ≥6 mm and CAL ≥5 mm. They had also ≥50% alveolar bone loss in at least two quadrants that was commensurate with amount of plaque accumulation. BOP was >50% in the whole mouth.

III. Gingivitis group (n=26). These individuals had varying degrees of gingival inflammation. They exhibited no sites with CAL >2 mm and no detectable alveolar bone loss in the radiography. BOP was >50% in the whole mouth.

IV. Healthy group (n=21). These periodontally healthy volunteers exhibited no sites with PD >3 mm and CAL >2 mm as well as no radiographic evidence of alveolar bone loss. BOP was \<15% in the whole mouth.

Saliva sampling

Whole unstimulated saliva samples were collected. Each participant was asked first to rinse the mouth completely with tap water for 2 minutes, wait for 10 minutes, and then expectorate into sterile polypropylene tube for 5 minutes.

Gingival crevicular fluid (GCF) sampling

Standardized filter paper strips were used for GCF sampling. Two GCF samples were taken from the buccal aspects of two non-adjacent interproximal sites of each individual. In patients with periodontitis, GCF were sampled from two sites exhibiting PD ≥6 mm and CAL ≥5 mm. GCF samples of gingivitis patients were obtained from the sites that exhibit BOP but no clinical attachment loss. In the healthy group, GCF samples were collected the sites exhibiting PD \<3 mm without BOP and clinical attachment loss.

Measurement of hypoxia inducible factor-1 alpha (HIF-1α), vascular endothelial growth factor (VEGF) and tumor necrosis factor-alpha (TNF-α) Levels in GCF and Saliva Samples

HIF-1α, VEGF and TNF-α levels in GCF and saliva samples were measured by the enzyme-linked immunosorbent assay (ELISA) using commercial kits according to the manufacturer's guidelines.

Statistical Analysis

All data analyses were performed using a statistical software package. Comparisons of clinical and biochemical parameters between the study groups were performed using the Kruskal-Wallis test.

02

Conditions studied

  • Periodontal Diseases

Browse trials for

Keywords

  • Periodontal disease
  • Hypoxia
  • Cytokines
  • Gingival crevicular fluid
  • Saliva
03

In context

Periodontal Diseases

830 studies on the registry are indexed under Periodontal Diseases; 188 are open to participants now.

This study's enrollment of 87 is below the median of 100 across 291 observational studies indexed under Periodontal Diseases.

Browse Periodontal Diseases studies →

Lead sponsor

Aydin Adnan Menderes University is the lead sponsor of 236 studies on the registry; 54 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
27 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

All consecutive individuals were recruited from the Department of Periodontology, School of Dentistry, Adnan Menderes University, Aydın.

Inclusion criteria

  1. Systemically healthy individuals
  2. Non-smoker individuals

Exclusion criteria

Exclusion Criteria:

  1. Current pregnancy or lactation
  2. Nonsurgical/surgical periodontal treatment received for the past year
  3. Use of anti-inflammatory and antibiotic drugs within the past 6 months.
05

Study design

Observational model
Case-control
Time perspective
Cross-sectional
Enrollment
87 participants (actual)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Aggressive Periodontitis

    These individuals had minimum PD ≥6 mm and CAL ≥5 mm on eight or more teeth; at least three of these were other than central incisors or first molars. Radiographic alveolar bone loss was ≥30% of root length affecting at least three permanent teeth other than first molars and incisors. The severe destruction pattern was not commensurate with amount of plaque accumulation.

  • Chronic periodontitis

    These individuals had at least four non-adjacent teeth with sites with PD ≥6 mm and CAL ≥5 mm. They had also ≥50% alveolar bone loss in at least two quadrants that was commensurate with amount of plaque accumulation. BOP was \>50% in the whole mouth.

  • Gingivitis

    Gingivitis patients exhibited no sites with CAL \>2 mm and no detectable alveolar bone loss in the radiography. BOP was \>50% in the whole mouth.

  • Healthy

    Periodontally healthy volunteers exhibited no sites with PD \>3 mm and CAL \>2 mm as well as no radiographic evidence of alveolar bone loss. BOP was \<15% in the whole mouth.

06

What researchers measure

Primary outcomes

  1. Gingival crevicular fluid HIF-1α levels

    pg

    Time frame: A day after clinical periodontal examination

Secondary outcomes

  1. Salivary HIF-1α levels

    pg/ml

    Time frame: A day after clinical periodontal examination

  2. Gingival crevicular fluid VEGF levels

    ng

    Time frame: A day after clinical periodontal examination

  3. Salivary VEGF levels

    ng/l

    Time frame: A day after clinical periodontal examination

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Afacan B, Ozturk VO, Pasali C, Bozkurt E, Kose T, Emingil G. Gingival crevicular fluid and salivary HIF-1alpha, VEGF, and TNF-alpha levels in periodontal health and disease. J Periodontol. 2019 Jul;90(7):788-797. doi: 10.1002/JPER.18-0412. Epub 2018 Dec 11. PubMed 30536725 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 15, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03558906
Lead sponsor
Aydin Adnan Menderes University
Collaborators
Celal Bayar University, Ege University
Responsible party
Beral Afacan (Assistant Professor, Aydin Adnan Menderes University) — Principal investigator
First posted
Jun 15, 2018
Start date
Mar 1, 2016
Primary completion
Mar 2, 2016
Completion
Dec 26, 2016
Last update
Jun 15, 2018

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion